ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Carisma Therapeutics Inc

Carisma Therapeutics Inc (CARM)

1.35
0.09
(7.14%)
Closed May 27 4:00PM
1.345
-0.005
(-0.37%)
After Hours: 7:59PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
1.35
Bid
1.32
Ask
1.37
Volume
190,603
1.2605 Day's Range 1.36
1.24 52 Week Range 9.7662
Market Cap
Previous Close
1.26
Open
1.31
Last Trade
1
@
1.32
Last Trade Time
Financial Volume
$ 248,045
VWAP
1.3014
Average Volume (3m)
170,699
Shares Outstanding
40,356,806
Dividend Yield
-
PE Ratio
-0.62
Earnings Per Share (EPS)
-2.15
Revenue
14.92M
Net Profit
-86.88M

About Carisma Therapeutics Inc

Carisma Therapeutics Inc. is a clinical-stage cell therapy company. The Company is focused on utilizing the Company¿s macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The Company has created a comprehensive cell t... Carisma Therapeutics Inc. is a clinical-stage cell therapy company. The Company is focused on utilizing the Company¿s macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The Company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells. The Company¿s lead product candidate, CT-0508, is a Chimeric Antigen Receptor Macrophage (CAR-M) to be evaluated in a human clinical trial and is intended to treat solid tumors that overexpress HER2. The Company¿s second product candidate, CT-0525, is also intended to treat solid tumors that overexpress HER2, is in preclinical development. Beyond CT-0508 and CT-0525, the Company has a pipeline of cell therapy assets in various stages of pre-clinical development. The Company is also developing in vivo CAR-M gene therapies. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Carisma Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CARM. The last closing price for Carisma Therapeutics was $1.26. Over the last year, Carisma Therapeutics shares have traded in a share price range of $ 1.24 to $ 9.7662.

Carisma Therapeutics currently has 40,356,806 shares outstanding. The market capitalization of Carisma Therapeutics is $54.08 million. Carisma Therapeutics has a price to earnings ratio (PE ratio) of -0.62.

CARM Latest News

Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte

Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte PR Newswire PHILADELPHIA, May 16, 2024 CT-0525 is the first...

Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights PR Newswire PHILADELPHIA, May 9, 2024 Announced CT-0525 as lead product candidate for anti-HER2...

Carmila: Réduction des moyens du contrat de liquidité

Regulatory News: Par contrat en date du 3 novembre 2023 la société Carmila SA (Paris:CARM) a confié à Kepler Cheuvreux la mise en œuvre d’un Contrat de Liquidité. Ce Contrat de Liquidité, doté...

Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024

Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024 PR Newswire PHILADELPHIA, May 8, 2024 Novel...

CARMILA: Information Concerning the Total Number of Voting Rights and Share

provided pursuant to article L.233-8 II of the Code de commerce (French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des marchés financiers (General regulation of...

Carisma Therapeutics to Participate in The Citizens JMP Life Sciences Conference

Carisma Therapeutics to Participate in The Citizens JMP Life Sciences Conference PR Newswire PHILADELPHIA, May 6, 2024 PHILADELPHIA, May 6, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq:...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.07-4.929577464791.421.4651.241936251.36000528CS
4-0.35-20.58823529411.71.70991.241606251.47214873CS
12-1.28-48.66920152092.632.771.241706991.91630228CS
26-1.19-46.85039370082.543.161.241731362.25523857CS
52-4.01-74.81343283585.369.76621.242212844.59609777CS
156-4.44-76.68393782385.799.76621.242140574.53174666CS
260-4.44-76.68393782385.799.76621.242140574.53174666CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
LUCYInnovative Eyewear Inc
$ 0.983
(428.49%)
944.4M
AKANAkanda Corporation
$ 4.07
(70.29%)
39.11M
TKLFYoshitsu Company Ltd
$ 0.3496
(53.33%)
84.5M
ONMDOneMedNet Corporation
$ 2.251
(53.13%)
136.04M
MRUSMerus NV
$ 59.92
(35.97%)
6.91M
VSTMVerastem Inc
$ 4.0901
(-66.42%)
19.68M
TOIIWOncology Institute Inc
$ 0.0443
(-55.61%)
280.55k
SNSESensei Biotherapeutics Inc
$ 0.7912
(-45.43%)
1.41M
GNLXGenelux Corporation
$ 2.61
(-43.26%)
3.32M
AUVIApplied UV Inc
$ 0.32
(-33.33%)
5.18M
LUCYInnovative Eyewear Inc
$ 0.983
(428.49%)
944.4M
GWAVGreenwave Technology Solutions Inc
$ 0.0843
(-4.85%)
428.98M
NCPLNetcapital Inc
$ 0.20
(14.42%)
191.35M
HLTHCue Health Inc
$ 0.0931
(-1.27%)
160.21M
ONMDOneMedNet Corporation
$ 2.251
(53.13%)
136.04M

Your Recent History

Delayed Upgrade Clock